• Stabilized IPTW was conducted to balance patient characteristics between the treatment cohorts within each
    database
  • Interaction analysis evaluated treatment effects of apixaban versus warfarin according to obesity status
  • Additionally, IPTW was conducted separately among obese and morbidly obese patients to ensure baseline
    characteristics were well-balanced between treatment cohorts for these subgroups
  • Cox proportional hazard models were used to evaluate the risk of recurrent VTE, MB, and CRNM bleeding for both
    the interaction analysis and the reweighted obese and morbidly obese subgroups